Crohn’s Disease Pipeline Insights, FDA Approvals, Drugs, Companies Report | DelveInsight
The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...
pharmaphorum1d
Pfizer’s Velsipity heading for NHS use in ulcerative colitis
The new guidance emerged on the same day that Velsipity (etrasimod) was approved by the Medicines ... It’s not the first drug in the class to become available for patients with moderate to ...
pharmaphorum1d
BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis
Another potential rival – Arena Pharma’s oral S1P etrasimod – is in late-stage ... which picked up an FDA approval for this indication last month to add to its current use in rheumatoid ...
Medical News Today2d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Forbes5d
Charlotte’s Web Founder Aims For FDA Approval Of Autism Spectrum Disorder Drug
Joel Stanley, former CEO of Charlotte’s Web, is part of a joint effort to achieve approval from the FDA for a novel treatment for the symptoms of autism spectrum disorder (ASD). Stanley is the ...
The American Journal of Managed Care6d
FDA Approves Mirikizumab for Crohn Disease
Omvoh's approval provides a new treatment option for Crohn's disease patients, especially those unresponsive to existing therapies. The FDA granted approval to Eli Lilly and Company’s ...
Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Medscape5d
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Reuters4d
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...
Monthly Prescribing Reference5d
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Hosted on MSN5d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...